Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should patients with malignancy receive chemoprophylaxis against Pneumocystis jirovecii pneumonia?

Nature Clinical Practice Oncology volume 2, pages 490–491 (2005)Cite this article

boxed-textWorth LJ et al. (2005) An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 92: 867–872

Immunocompromised patients under prolonged administration of corticosteroids should receive chemoprophylaxis against PCP with TMP–SMX, according to perceived risk, if not otherwise contraindicated

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Barbounis V et al. (2005) Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res 25: 651–655

    PubMed  Google Scholar 

  2. Yale SH and Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 71: 102–103

    Article  Google Scholar 

  3. Hughes WT et al. (1987) Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 316: 1627–1632

    Article  CAS  PubMed  Google Scholar 

  4. Walzer P (2000) Pneumocystis carinii. In Principles and Practice of Infectious Diseases, edn 5, 2789 (Eds Mandell et al.) New York: Churchill Livingstone

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Deputy Director of the Department of Medical Oncology at the St Savas Cancer Hospital, Athens, Greece

    Vassilios Barbounis

Authors
  1. Vassilios Barbounis
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barbounis, V. Should patients with malignancy receive chemoprophylaxis against Pneumocystis jirovecii pneumonia?. Nat Rev Clin Oncol 2, 490–491 (2005). https://doi.org/10.1038/ncponc0299

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0299

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing